When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis?

被引:24
作者
Lorenzoni, Paulo Jose [1 ]
Werneck, Lineu Cesar [1 ]
Kamoi Kay, Claudia Suemi [1 ]
Soares Silvado, Carlos Eduardo [1 ]
Scola, Rosana Herminia [1 ]
机构
[1] Univ Fed Parana, Hosp Clin, Dept Clin Med, Serv Neurol & Doencas Neuromusculares, BR-80060000 Curitiba, Parana, Brazil
关键词
MELAS; mitochondria; myopathy; stroke; encephalopathy; genetics; TRANSFER RNALEU(UUR) GENE; MUSCLE-FIBER ANALYSIS; C-OXIDASE DEFICIENCY; RAGGED-RED FIBERS; POINT MUTATION; CLINICAL-FEATURES; BLOOD-VESSELS; VASCULAR INVOLVEMENT; MOLECULAR-GENETICS; DNA MUTATION;
D O I
10.1590/0004-282X20150154
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) is a rare mitochondrial disorder. Diagnostic criteria for MELAS include typical manifestations of the disease: stroke-like episodes, encephalopathy, evidence of mitochondrial dysfunction ( laboratorial or histological) and known mitochondrial DNA gene mutations. Clinical features of MELAS are not necessarily uniform in the early stages of the disease, and correlations between clinical manifestations and physiopathology have not been fully elucidated. It is estimated that point mutations in the tRNA(Leu(UUR)) gene of the DNAmt, mainly A3243G, are responsible for more of 80% of MELAS cases. Morphological changes seen upon muscle biopsy in MELAS include a substantive proportion of ragged red fibers (RRF) and the presence of vessels with a strong reaction for succinate dehydrogenase. In this review, we discuss mainly diagnostic criterion, clinical and laboratory manifestations, brain images, histology and molecular findings as well as some differential diagnoses and current treatments.
引用
收藏
页码:959 / 967
页数:9
相关论文
共 60 条
[1]   Comparison of conventional and diffusion-weighted MRI and proton MR spectroscopy in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like events [J].
Abe, K ;
Yoshimura, H ;
Tanaka, H ;
Fujita, N ;
Hikita, T ;
Sakoda, S .
NEURORADIOLOGY, 2004, 46 (02) :113-117
[2]   Atypical MELAS syndrome associated with a new mitochondrial tRNA glutamine point mutation [J].
Bataillard, M ;
Chatzoglou, E ;
Rumbach, L ;
Sternberg, D ;
Tournade, A ;
Laforêt, P ;
Jardel, C ;
Maisonobe, T ;
Lombès, A .
NEUROLOGY, 2001, 56 (03) :405-407
[3]   Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement [J].
Betts, J. ;
Jaros, E. ;
Perry, R. H. ;
Schaefer, A. M. ;
Taylor, R. W. ;
Abdel-All, Z. ;
Lightowlers, R. N. ;
Turnbull, D. M. .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2006, 32 (04) :359-373
[4]   MELAS - CLINICAL-FEATURES, BIOCHEMISTRY, AND MOLECULAR-GENETICS [J].
CIAFALONI, E ;
RICCI, E ;
SHANSKE, S ;
MORAES, CT ;
SILVESTRI, G ;
HIRANO, M ;
SIMONETTI, S ;
ANGELINI, C ;
DONATI, MA ;
GARCIA, C ;
MARTINUZZI, A ;
MOSEWICH, R ;
SERVIDEI, S ;
ZAMMARCHI, E ;
BONILLA, E ;
DEVIVO, DC ;
ROWLAND, LP ;
SCHON, EA ;
DIMAURO, S .
ANNALS OF NEUROLOGY, 1992, 31 (04) :391-398
[5]   Screening for MELAS mutations in young patients with stroke of undetermined origin [J].
Conforto, Adriana Bastos ;
Yamamoto, Fabio luji ;
Oba-Shinjo, Sueli Mieko ;
Pinto, Julio Guy C. ;
Hoshino, Mauricio ;
Scaff, Milberto ;
Marie, Suely Kazue Nagahashi .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2007, 65 (2B) :371-376
[6]  
DiMauro S., 2013, GeneReviews
[7]   Genetic, pathogenetic, and phenotypic implications of the mitochondrial A3243G tRNALeu(UUR) mutation [J].
Finsterer, J. .
ACTA NEUROLOGICA SCANDINAVICA, 2007, 116 (01) :1-14
[8]   Management of mitochondrial stroke-like-episodes [J].
Finsterer, J. .
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (11) :1178-1184
[9]  
Finsterer Josef, 2012, Open Neurol J, V6, P26, DOI 10.2174/1874205X01206010026
[10]   Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders [J].
Finsterer, Josef ;
Mahjoub, Sinda Zarrouk .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (01) :71-79